HC Wainwright Forecasts Stronger Earnings for Shattuck Labs

Shattuck Labs, Inc. (NASDAQ:STTK) – Equities researchers at HC Wainwright boosted their Q1 2026 earnings per share (EPS) estimates for Shattuck Labs in a report issued on Monday, April 20th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.17) for the quarter, up from their previous forecast of ($0.18). HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Shattuck Labs’ Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($0.79) EPS.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). The firm had revenue of ($1.00) million during the quarter, compared to analysts’ expectations of $0.17 million.

A number of other analysts also recently issued reports on STTK. Citigroup lifted their price objective on Shattuck Labs from $4.00 to $7.00 and gave the stock a “neutral” rating in a research note on Friday, March 13th. Wall Street Zen raised Shattuck Labs from a “hold” rating to a “buy” rating in a research report on Saturday, March 28th. Piper Sandler began coverage on Shattuck Labs in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $15.00 price objective on the stock. Wedbush upped their target price on Shattuck Labs from $4.00 to $8.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. Finally, TD Cowen restated a “buy” rating on shares of Shattuck Labs in a research note on Friday, March 6th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Shattuck Labs presently has an average rating of “Moderate Buy” and a consensus price target of $12.50.

Shattuck Labs Stock Down 1.5%

STTK stock opened at $7.76 on Wednesday. The business’s 50-day moving average price is $5.70 and its 200-day moving average price is $3.93. Shattuck Labs has a twelve month low of $0.71 and a twelve month high of $8.33. The stock has a market cap of $586.50 million, a P/E ratio of -10.08 and a beta of 1.28.

Hedge Funds Weigh In On Shattuck Labs

Hedge funds and other institutional investors have recently made changes to their positions in the company. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Shattuck Labs in the third quarter valued at approximately $29,000. Virtu Financial LLC purchased a new position in Shattuck Labs during the third quarter worth approximately $38,000. Squarepoint Ops LLC purchased a new position in Shattuck Labs during the third quarter worth approximately $46,000. Mallini Complete Financial Planning LLC purchased a new position in Shattuck Labs during the fourth quarter worth approximately $83,000. Finally, Dimensional Fund Advisors LP purchased a new position in Shattuck Labs during the fourth quarter worth approximately $85,000. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.